Copyright © 2002 by the European Society of Cardiology.
The endothelial nitric oxide synthase (Glu298Asp and –786T>C) gene polymorphisms are associated with coronary in-stent restenosis
a National Heart and Lung Institute, Royal Brompton Hospital, Imperial College of Science, Technology & Medicine, London, U.K.
b British Heart Foundation Laboratories for Cardiovascular Genetic Studies, Royal Free UCL Medical School, London, U.K.
c London Chest Hospital, London, U.K.
revised August 27, 2002; accepted September 11, 2002
Abstract
Aims Coronary stent deployment is a major advance in percutaneous treatment of ischaemic heart disease, but 10–40% of patients still develop angiographic restenosis by 6 months due to neointimal hyperplasia. Patient-specific factors, including genetic factors, can contribute to this process. We have conducted a prospective study to examine the involvement of genetic risk factors (eNOS, ACE, MMP-3, IL-6, and PECAM-1) in restenosis following coronary stent deployment.
Methods and Results A total of 226 patients who underwent elective and successful coronary artery stenting to de novo lesions in native coronary arteries were studied. Two hundred and five (90·7%) patients were restudied by coronary angiogram at 6 months and the stented lesions were assessed using an automated quantitative angiography system. Genotype was determined by polymerase chain reaction (PCR) and restriction enzyme digestion. Restenosis rate, defined as 
50% diameter stenosis, was 29·3%. The overall genotype frequency distributions were in Hardy–Weinberg equilibrium for all variants. Carriers of the 298Asp allele of the eNOS Glu298Asp polymorphism showed a higher frequency of restenosis with an odds ratio of 1·88 (95%CI: 1·01–3·51, P=0·043) compared to 298Glu homozygotes. Carriers of the –786C allele of the eNOS –786T>C polymorphism also showed a higher frequency of restenosis with odds ratio of 2·06 (95%CI: 1·08–3·94, P=0·028). These effects were essentially additive and were independent of other classical risk factors. Other studied genes did not show significant association with coronary in-stent restenosis.
Conclusion In patients with coronary artery disease, the possession of the 298Asp and –786C variants of the eNOS gene are a risk factor for coronary in-stent restenosis, demonstrating the importance of the nitric oxide system in restenosis. Copyright 2002 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved.
Key Words: eNOS polymorphism, restenosis, stents, genes, angiography.
f1 Correspondence: Dr A. H. Gomma, Cardiology Department, Royal Brompton Hospital, Sydney Street, London, SW3 6NP, U.K.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Galluccio, P. Piatti, L. Citterio, P. C. G. Lucotti, E. Setola, L. Cassina, M. Oldani, I. Zavaroni, E. Bosi, A. Colombo, et al. Hyperinsulinemia and impaired leptin-adiponectin ratio associate with endothelial nitric oxide synthase polymorphisms in subjects with in-stent restenosis Am J Physiol Endocrinol Metab, May 1, 2008; 294(5): E978 - E986. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Casas, G. L. Cavalleri, L. E. Bautista, L. Smeeth, S. E. Humphries, and A. D. Hingorani Endothelial Nitric Oxide Synthase Gene Polymorphisms and Cardiovascular Disease: A HuGE Review Am. J. Epidemiol., November 15, 2006; 164(10): 921 - 935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P R Kalra, A Gomma, C Daly, J R Clague, I B Squire, L L Ng, and K F Fox Reduction in plasma concentrations of N terminal pro B type natriuretic peptide following percutaneous coronary intervention Heart, November 1, 2004; 90(11): 1334 - 1335. [Full Text] [PDF]
|
|